Regenerex Pharma (RGPX) Equity Average (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Equity Average data on file, last reported at -$4.6 million in Q3 2025.

• Equity Average for Q3 2025 came in at -$4.6 million, down 1.94% year-over-year; the trailing twelve-month figure through Sep 2025 was -$4.6 million (down 1.94% YoY), and the FY2025 annual result was -$4.1 million, down 58.5% from the prior year.
• Equity Average slipped to -$4.6 million in Q3 2025 per RGPX's latest filing, from -$4.4 million in the prior quarter.
• Over five years, Equity Average peaked at -$692786.0 in Q1 2021 and troughed at -$4.9 million in Q4 2024.
• A 5-year average of -$2.5 million and a median of -$1.1 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average slumped 279.5% in 2024, then slipped 1.94% in 2025.
• A 5-year view of Equity Average shows it stood at -$919951.0 in 2021, then decreased by 14.35% to -$1.1 million in 2022, then tumbled by 256.93% to -$3.8 million in 2023, then slumped by 30.65% to -$4.9 million in 2024, then rose by 5.75% to -$4.6 million in 2025.
• Business Quant data shows RGPX's Equity Average at -$4.6 million in Q3 2025, -$4.4 million in Q2 2025, and -$4.6 million in Q1 2025.